The hypoxic response of tumors is dependent on their microenvironment.

To reveal the functional significance of hypoxia and angiogenesis in astrocytoma progression, we created genetically engineered transformed astrocytes from murine primary astrocytes and deleted the hypoxia-responsive transcription factor HIF-1alpha or its target gene, the angiogenic factor VEGF. Growth of HIF-1alpha- and VEGF-deficient transformed astrocytes in the vessel-poor subcutaneous environment results in severe necrosis, reduced growth, and vessel density, whereas when the same cells are placed in the vascular-rich brain parenchyma, the growth of HIF-1alpha knockout, but not VEGF knockout tumors, is reversed: tumors deficient in HIF-1alpha grow faster, and penetrate the brain more rapidly and extensively. These results demonstrate that HIF-1alpha has differential roles in tumor progression, which are greatly dependent on the extant microenvironment of the tumor.

[1]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[2]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[3]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[4]  A. Pawson,et al.  Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.

[5]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[6]  R. Kerbel,et al.  Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras , 1999, International journal of cancer.

[7]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[8]  A. Taghian,et al.  Growth and metastatic behavior of five human glioblastomas compared with nine other histological types of human tumor xenografts in SCID mice. , 1995, Journal of neurosurgery.

[9]  R. Rickert,et al.  Hypoxia-Inducible Factor 1 (cid:2) Is Essential for Cell Cycle Arrest during Hypoxia , 2002 .

[10]  Daniel J Brat,et al.  Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. , 2003, Frontiers in bioscience : a journal and virtual library.

[11]  R K Jain,et al.  Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. , 2000, Cancer research.

[12]  E. Holland,et al.  Glioblastoma multiforme: the terminator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.

[14]  R. Weinberg,et al.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. , 2003, Cancer cell.

[15]  Hiroyuki Shimada,et al.  Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.

[16]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[17]  D. Hanahan,et al.  The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. , 1996, Genes & development.

[18]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[19]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[20]  Erwin G. Van Meir,et al.  Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation , 2002, Advances in anatomic pathology.

[21]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[22]  J. Folkman.  Tumor angiogenesis. , 1985, Advances in cancer research.

[23]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[24]  G. Semenza.  Involvement of hypoxia-inducible factor 1 in human cancer. , 2002, Internal medicine.

[25]  J. M. Arbeit,et al.  Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .

[26]  R. Wenger,et al.  The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. , 2003, Oncogene.

[27]  D. Louis,et al.  Glioma classification: a molecular reappraisal. , 2001, The American journal of pathology.

[28]  D. Gutmann,et al.  Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. , 2001, Cancer research.

[29]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[30]  K. Kondo,et al.  SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. , 2000, Anticancer Research.

[31]  K. Lamborn,et al.  Characterization of human glioblastoma xenograft growth in athymic mice. , 1998, In vivo.

[32]  D. Hanahan,et al.  Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. , 1999, Cancer research.

[33]  P. Pandolfi,et al.  Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. , 2002, Cancer cell.

[34]  S. Hussain,et al.  Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[35]  P. Brenchley,et al.  Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas , 2001, Histopathology.

[36]  L. Taillandier,et al.  Models for neuro-oncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice , 2003, Journal of Neuroscience Methods.

[37]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[39]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[40]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[41]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[42]  H. Takita,et al.  Orthotopic engraftment of human lung tumours in SCID mice for the study of metastasis. , 1996, Surgical oncology.

[43]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.